Navigation Links
NEBIDO in Medical News

Men with Low Testosterone See Multiple Doctors Before Being Diagnosed; Many Dissatisfied with Current Treatment Options

...currently is pending U.S. Food and Drug Administration approval. Testosterone undecanoate was first approved in Europe in 2003 and is now marketed as nebido in more than 80 countries by Bayer Schering Pharma AG. ABOUT HYPOGONADISM Hypogonadism, also known as low testosterone, is a common yet la...

Testosterone Undecanoate Achieves and Maintains Normal Testosterone Levels in Hypogonadal Men With Five Injections Per Year, New Data Show

...thin the normal range over the 21-month study, and nebido was generally well tolerated. The long-term clini...rmal range throughout the 21-month study, and that nebido was generally well tolerated. nebido is currently under review at the U.S. Food and Dru...

Indevus Pharmaceuticals Announces Definitive Merger Agreement With Endo Pharmaceuticals

... upon achievement of certain milestones related to nebido (R) (in development for hypogonadism) and the octr...ant interest in the downstream value creation from nebido and the octreotide implant. "Our employees, w...r. "Our sales force, Cranbury operations, and the nebido and Octreotide R&D teams are expected to play ...

Endo Pharmaceuticals to Acquire Indevus Pharmaceuticals

...signed for easy, in-office physician insertion under local anesthesia. nebido is a novel, long-acting injectable testosterone depot being developed for t...to support regulatory review of the company's pending application to market nebido as the first long-acting testosterone preparation available in the United S...

Indevus Pharmaceuticals Announces Third Quarter Fiscal 2008 Financial Results

...cipate being able to discuss our future plans with nebido in the coming months. "Our portfolio of marketed...gn our expense structure with the realities of the nebido delay," stated Dr. Cooper. "Our new operating plan...acement therapies. Indevus acquired U.S. rights to nebido from Bayer Schering Pharma AG, Germany in July 200...

Indevus Pharmaceuticals Provides Update on NEBIDO(R) NDA Status

...aneous post-marketing adverse event reports of the nebido 1000 mg (4ml) dose. In the Indevus U.S. clinical t...orts on patients having received the 1000 mg (4ml) nebido dose, FDA has asked for new data to more precisely... the FDA is taking regarding the safety profile of nebido given the large European experience. Rare coughing...

FDA Accepts New Drug Application for NEBIDO(R) Submitted by Indevus

...n Drug User Fee Act (PDUFA) target action date for nebido is June 27, 2008. The NDA was submitted to the FDA...nce from over 260,000 injections of NEBIDO. About nebido NEBIDO(R) is a long-acting depot preparation of t... developed for the treatment of male hypogonadism. nebido is expected to be the first three-month testostero...
NEBIDO in Medical Technology

Indevus Reports Positive Data From Phase III NEBIDO Trial

Compound Achieves All Key Endpoints for Both Efficacy and Safety LEXINGTON, Mass., June 07, 2007 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. today announced final results from its Phase III pharmacokinetic trial for NEBIDO (testosterone undecanoate), a long- acting injectable testoster...

FDA Accepts Complete Response Submission to New Drug Application for NEBIDO(R)

...pleased with the FDA's action and congratulate the nebido development team on reaching this milestone. We l...ook forward to receiving the FDA's decision on the nebido marketing application in September." About nebido ...

Indevus Presents Successful Phase III NEBIDO(R) Data at American Urological Association

...riteria. Patients received injections of 750 mg of nebido at baseline, week 4, and week 14 of the study, and... developed for the treatment of male hypogonadism. nebido is expected to be the first long-acting testostero...sterone therapies. Indevus acquired U.S. rights to nebido from Bayer Schering Pharma AG, Germany in July 200...

Indevus Reports Additional Positive Phase III Trial Data for NEBIDO(R)

... Company Files Additional Data to the nebido NDA PDUFA Date Expected to Remain Jun...al positive results from its Phase III program for nebido (testosterone undecanoate), a long-acting injectab...n Drug User Fee Act (PDUFA) target action date for nebido will remain June 27, 2008. The dosing regimen fo...

Indevus Announces Submission of New Drug Application

... Seeking Approval for nebido to Treat Male Hypogonadism LEXINGTON, Mass., Aug...ny) which has formed the basis for the approval of nebido in over 75 countries to date. The U.S. testostero...,000 injections of NEBIDO. "The submission of the nebido NDA is a very important milestone for the Company,...
NEBIDO in Biological Technology

Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results

...ghts During the past year, the Company achieved a number of important milestones, including: Clinical Development -- Results From nebido Phase III Trial Shows 94 Percent of Men Maintained Normal Testosterone Levels Throughout Treatment -- Results From Two-Year Study Confirmin...

Indevus and FDA Agree on Path Forward for NEBIDO(R)

...rge, simple post- marketing study of the safety of nebido in approximately 10,000 patients. "We are very p...uming approval, we will be in a position to launch nebido with our sales force in the fourth quarter of cale...osterone therapy and we expect the introduction of nebido to have a significant positive impact on the Compa...

Indevus Receives Approvable Letter from FDA for NEBIDO(R)

...any Announces Revised Operating Plan to Respond to nebido Delay LEXINGTON, Mass., June 30 /PRNewswire-Firs...mediately following the intramuscular injection of nebido 1000 mg, 4 cc injection volume, (versus the 750 mg...fainting. In the Company's U.S. clinical trials of nebido 750 mg (3 cc injection volume), the proposed dose ...
Other Tags
(Date:7/13/2014)... July 13, 2014 MarketsandMarkets recently ... [3D Modeling; 3D Scanning; 3D rendering; Layout and ... Analysis (2013 - 2018)”, which analyzes and studies ... North America, Western Europe, Eastern Europe, Middle East ... also draws the competitive landscape of the 3D ...
(Date:7/13/2014)... Athletes with a certain genetic make-up ... according to research presented today at the American Orthopaedic ... The research marks the first of its kind investigating ... physical events that occur after a head injury. ... in the (GT)n genotype were four times more likely ...
(Date:7/13/2014)... 2014 Recently, MyDressCity.com, one of the ... occasion outfits, has released its new range of ... products are available at discounted prices. Worldwide clients can ... , In the company’s online shop, there are plenty ... are made with great materials. MyDressCity.com’s hot items are ...
(Date:7/13/2014)... COPENHAGEN, July 13, 2014 A decreased ability ... cognitive impairment and Alzheimer,s disease, while examinations of ... a protein associated with Alzheimer,s, in the brain, ... reported today at the Alzheimer,s Association International Conference ... of the studies, the decreased ability to identify ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 Celebrity fitness ... has formed a promotional partnership with Aqua Health Labs ... Omega-3 EPA supplement . The collaboration was recently ... celebrity fitness trainer , actor, model, and a ... trainer for A-List celebrities, he has prepared stars including ...
Breaking Medicine News(10 mins):Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 2Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 3Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 4Health News:Genetic Factors May Be Responsible for Slowing Concussion Recovery in Athletes 2Health News:Cheap Elegant Quinceanera Dresses Unveiled by MyDressCity.com 2Health News:Smell and eye tests show potential to detect Alzheimer's early 2Health News:Smell and eye tests show potential to detect Alzheimer's early 3Health News:Smell and eye tests show potential to detect Alzheimer's early 4Health News:Smell and eye tests show potential to detect Alzheimer's early 5Health News:Smell and eye tests show potential to detect Alzheimer's early 6Health News:Smell and eye tests show potential to detect Alzheimer's early 7Health News:Celebrity Fitness Expert Supports Revolutionary New Health Supplement 2
(Date:7/10/2014)... 30, 2014  Aware, Inc. (NASDAQ: AWRE ... previously announced on June 26, 2014 that its Board ... $1.75 per share, or approximately $40 million in total.  ... 2014 and a payment date of July 24, 2014.  ... had set an ex-dividend date for this special cash ...
(Date:7/10/2014)... July 2, 2014  Unisys Corporation,s (NYSE: UIS ... Nederland N.V., today announced that it has been selected by ... manage a new Basic Provision Biometrics solution for penitentiaries across ... won the contract with a solution based on its open ... term of the contract is up to seven years, with ...
(Date:7/10/2014)... , July 2, 2014 NXT-ID, Inc., (OTCQB: NXTD) a biometric ... CEO Mr. Gino Pereira was interviewed on July ... Tampa Florida . Mr. Pereira discusses the ... Cedric Harris and how the Wocket™ aims to replace ... Cedric Harris tells Gino he has ...
Breaking Biology News(10 mins):NASDAQ Sets Ex-Dividend Date for Aware, Inc.'s Special Cash Dividend of $1.75 Per Share 2Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 2Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 2Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 4
Other Contents